KIX 92.1Oldies 98.397.9 The BeatQ-102Delta Country 105.7Star 101KIX 92.7WNIXWNLA AM 1380



Existing Drug Reduces Covid-19 Infection By Up To 70%

Maybe unapproved vaccines aren’t the answer to ending the COVID-19 pandemic.

A licensed drug normally used to treat abnormal levels of fatty substances in the blood could reduce infection caused by the SARS-CoV-2 virus by up to 70 per cent, reveals a study in the laboratory by an international collaboration of researchers.

The research team, led by the University of Birmingham and Keele University in the UK and the San Raffaele Scientific Institute in Italy, has demonstrated that fenofibrate and its active form (fenofibric acid) can significantly reduce SARS-COV-2 infection in human cells in the laboratory. Importantly, reduction of infection was obtained using concentrations of the drug which are safe and achievable using the standard clinical dose of fenofibrate.

Fenofibrate, which is approved for use by most countries in the world including the US Food and Drug Administration (FDA) and the UK’s National Institute for Health and Care Excellence (NICE), is an oral drug currently used to treat conditions such as high levels of cholesterol and lipids (fatty substances) in the blood.

The team is now calling for clinical trials to test the drug in hospitalized COVID-19 patients, to be carried out in addition to two clinical trials also currently underway in such patients in research being led by the Hospital of the University of Pennsylvania in the US and Hebrew University of Jerusalem in Israel.

 

Contact Jay Allen at [email protected]

 

MORE FROM DELTA DAILY NEWS

Feds Consider Withholding Funds To Encourage Vaccinations

Leave a Reply

Your email address will not be published. Required fields are marked *